<li>caffeine<p>caffeine decreases levels of levothyroxine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. COFFEE binds levothyroxine in the GI tract.  Separate by 2 hours.</p></li><li>calcium acetate<p>calcium acetate decreases levels of levothyroxine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate administration by 4 hours.</p></li><li>calcium carbonate<p>calcium carbonate decreases levels of levothyroxine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hours.</p></li><li>calcium chloride<p>calcium chloride decreases levels of levothyroxine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hours.</p></li><li>calcium citrate<p>calcium citrate decreases levels of levothyroxine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hours.</p></li><li>calcium gluconate<p>calcium gluconate decreases levels of levothyroxine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hours.</p></li><li>carbonyl iron<p>carbonyl iron decreases levels of levothyroxine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>cholestyramine<p>cholestyramine decreases levels of levothyroxine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>colesevelam<p>colesevelam decreases levels of levothyroxine by drug binding in GI tract. Use Caution/Monitor. Concomitant administration decreases levothyroxine absorption; however, absorption is not reduced when levothyroxine is administered 4 hr before colesevelam.</p></li><li>crofelemer<p>crofelemer increases levels of levothyroxine by Other (see comment). Use Caution/Monitor. 
Comment: Crofelemer has the potential to inhibit transporters MRP2 and OATP1A2 at concentrations expected in the gut; unlikely to inhibit systemically because minimally absorbed.</p></li><li>cyclosporine<p>cyclosporine will increase the level or effect of levothyroxine by  Other (see comment). Use Caution/Monitor. may increase plasma concentrations of OATP substrates</p></li><li>daclatasvir<p>daclatasvir will increase the level or effect of levothyroxine by  Other (see comment). Use Caution/Monitor. Daclatasvir inhibits OATP1B1, OATP1B3, and BCRP. Caution if coadministered with drugs that are substrates of these transporters.</p></li><li>didanosine<p>didanosine will decrease the level or effect of levothyroxine by  inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Applies to didanosine chewable tablets and powder for oral solution; administer 2 hr before or several hours after didanosine oral solution or chewable tablet administration</p></li><li>digoxin<p>levothyroxine decreases effects of digoxin by unknown mechanism. Use Caution/Monitor.</p></li><li>dulaglutide<p>dulaglutide, levothyroxine. Other (see comment). Use Caution/Monitor. 
Comment: Dulaglutide slows gastric emptying and may impact absorption of concomitantly administered oral medications; be particularly cautious when coadministered with drugs that have a narrow therapeutic index.</p></li><li>eluxadoline<p>eluxadoline increases levels of levothyroxine by decreasing metabolism. Use Caution/Monitor. Eluxadoline may increase the systemic exposure of coadministered OATP1B1 substrates.</p></li><li>ferrous fumarate<p>ferrous fumarate decreases levels of levothyroxine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>ferrous gluconate<p>ferrous gluconate decreases levels of levothyroxine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>ferrous sulfate<p>ferrous sulfate decreases levels of levothyroxine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>food<p>food decreases levels of levothyroxine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. COFFEE binds levothyroxine in the GI tract.  Separate by 2 hours.</p></li><li>insulin degludec<p>levothyroxine decreases effects of insulin degludec by pharmacodynamic antagonism. Use Caution/Monitor. Thyroid hormones regulate carbohydrate metabolism, gluconeogenesis, and glycogen stores mobilization; dose of antidiabetic agents may need adjustment and increased frequency of glucose monitoring may be required.</p></li><li>insulin degludec/insulin aspart<p>levothyroxine decreases effects of insulin degludec/insulin aspart by pharmacodynamic antagonism. Use Caution/Monitor. Thyroid hormones regulate carbohydrate metabolism, gluconeogenesis, and glycogen stores mobilization; dose of antidiabetic agents may need adjustment and increased frequency of glucose monitoring may be required.</p></li><li>insulin inhaled<p>levothyroxine decreases effects of insulin inhaled by pharmacodynamic antagonism. Use Caution/Monitor. Thyroid hormones regulate carbohydrate metabolism, gluconeogenesis, and glycogen stores mobilization; dose of antidiabetic agents may need adjustment and increased frequency of glucose monitoring may be required.</p></li><li>iron dextran complex<p>iron dextran complex decreases levels of levothyroxine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>iron sucrose<p>iron sucrose decreases levels of levothyroxine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>lanthanum carbonate<p>lanthanum carbonate decreases levels of levothyroxine by cation binding in GI tract. Use Caution/Monitor. Administer oral thyroid products at least 2 hr before or after lanthanum. Interaction applies only to oral thyroid products only. .</p></li><li>nateglinide<p>levothyroxine decreases effects of nateglinide by pharmacodynamic antagonism. Use Caution/Monitor. Coadministration may reduce nateglinide's hypoglycemic action.</p></li><li>ombitasvir/paritaprevir/ritonavir<p>ombitasvir/paritaprevir/ritonavir will increase the level or effect of levothyroxine by  Other (see comment). Use Caution/Monitor. Paritaprevir inhibits OATP1B1, OATP1B3, and BCRP. Ritonavir inhibits BCRP. Caution if coadministered with drugs that are substrates of these transporters.</p></li><li>orlistat<p>orlistat decreases levels of levothyroxine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Risk of hypothyroidism. Separate by 4 hours.</p></li><li>patiromer<p>patiromer will decrease the level or effect of levothyroxine by  drug binding in GI tract. Use Caution/Monitor. May administer  3 hours apart</p></li><li>polysaccharide iron<p>polysaccharide iron decreases levels of levothyroxine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>raloxifene<p>raloxifene decreases levels of levothyroxine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>rose hips<p>rose hips decreases levels of levothyroxine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>teduglutide<p>teduglutide increases levels of levothyroxine by Other (see comment). Use Caution/Monitor. 
Comment: Teduglutide may increase absorption of concomitant PO medications; caution with with drugs requiring titration or those with a narrow therapeutic index; dose adjustment may be necessary.</p></li><li>trimagnesium citrate anhydrous<p>trimagnesium citrate anhydrous decreases levels of levothyroxine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.</p></li>